Contrary to what drugmakers are purporting, price hikes on drugs are not the result of rebates, according to a study commissioned by the Pharmaceutical Care Management Association.
Based on an analysis by Visante of price growth and estimated rebate levels for the top 200 brand drugs by 2016 U.S. sales, the PCMA study finds no correlation between the increasing prices that drugmakers set on individual drugs and the rebates they negotiate with pharmacy benefit managers on those products.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.